08.01.2016 - A new hope for gene therapy: Dutch biotech uniQure has presented promising results from its haemophilia B gene therapy clinical trial. A jump in the company’s shares followed the announcement.
In a low-dose cohort of an ongoing Phase I/II clinical trial being conducted in adult hemophilia B patients, uniQures AAV5/FIX gene therapy, AMT-060, has resulted in encouraging data. Topline results showed that four out of the five patients were able to discontinue prophylactic recombinant factor IX. Two patients’ factor IX rose to 5.5% and 4.5% of the normal level, from below 2% before the treatment.
Haemophilia B patients themselves cannot produce enough factor IX, a protein responsible for blood clotting, leading to excessive bleeding. Patients are currently treated by repeated infusion of recombinant factor IX. uniQure’s gene therapy AMT-060 consists of a codon-optimised wild type FIX gene and the LP1 liver promoter together with the AAV5 viral vector, manufactured using uniQure’s insect cell based manufacturing technology. AMT-060 is administered, without immunosuppressant therapy, through the peripheral vein in a one treatment session for approximately 30 minutes.
“These early data from the low-dose cohort suggest that AMT-060 is generally well-tolerated and capable of successfully transducing the liver resulting in clinically meaningful FIX expression levels,” uniQure said in a statement. Frank W.G. Leebeek an investigator in the study at the Erasmus Medical Center in Rotterdam, added: “Thus far, the overall tolerability and FIX expression profile in the low-dose cohort is encouraging for patients with hemophilia B and support the continuation of the study.”
Shareholders shared the company’s optimism. uniQure’s shares rose from below US$15 on 6th January, to more than US$17 on the 8th.
“Today, we are the only AAV gene therapy company in the world with both proprietary, commercial-scale manufacturing capabilities and encouraging clinical data across multiple diseases,” commented uniQure CEO Dan Soland.
27.07.2016 In view of the Brexit, research academies across Britain are calling for a “bold commitment” from the government. The Royal Society President urges the UK government to underwrite the research of British scientists applying for EU funding.
20.07.2016 Belgian molecular diagnostics company Biocartis Group NV has raised €55m and will use the funds mainly to expand manufacturing capacities for its PCR-based molecular diagnostics system Idylla.
19.07.2016 It is Europe’s first gene therapy company to float on Euronext: Gensight raised €40m in its IPO. And it is not the only French company that has taken the leap in an uncertain market climate – Alzheimer’s expert Pharnext also went public.
18.07.2016 When NASA blasted off to the International Space Station on Monday morning, it had UK tech on board. A miniature DNA sequencer from Oxford Nanopore will be used to keep an eye on the ISS atmosphere – and may even analyse alien DNA one day.
13.07.2016 Cell Medica has acquired Swiss antibody specialist Delenex Therapeutics. The deal nets the British cellular therapeutics developer Delenex’ proprietory antibody fragment platform Pentrabody.
12.07.2016 Vienna-based vaccine specialist Themis Bioscience GmbH has secured broad access to a promising virus vaccine vector tech by extending its license agreement with French Institut Pasteur. Its goal: to develop a Zika vaccine.
07.07.2016 Californian biopharma Medivation has agreed to confidential negotiations with its suitors, in particular the French pharmaceutical company Sanofi, which aggressively has buffeted the cancer therapy specialist for months.
06.07.2016 The European Commission started an investigation into Illumina’s and Sequenom’s 2014 patent agreement, UK-competitor Premaitha Health said. The two US companies had agreed to pool their Noninvasive Prenatal Testing IP.
04.07.2016 Cinfa Biotech is shuffling for position on the lucrative biosimilar market. The Spanish-German company has published positive results in a study for a pegfilgrastim copycat with 172 healthy volunteers in Germany.
30.06.2016 UK’s Heptares Therapeutics and Paul Scherrer Institute spinoff leadXpro will collaborate to find new approaches for the determination of high-res X-ray structures of G protein-coupled receptors to find new drugs.
JANUS® G3 Automation Workstations deliver real-time and future adaptability in throughput, capacity, and dynamic volume range from 0.5 μl to 5000 μl for consistent and reproducible sample preparation more